The mission of the Pharmacology Core Facility (PCF) is to foster clinical pharmacology and biomarker research regarding cancer therapeutics. The Facility offers comprehensive lab services to support cancer investigators conducting clinical and preclinical drug development studies. The PCF is now comprised of an Analytical Unit and a Biofluids Unit. The labs occupy -3,465 sq ft of space within the Section of Hematology/Oncology, and also utilizes the IV therapy unit (2,662 sq ft) located directly across from the Hematology/Oncology clinic in the Duchossois Center for Advanced Medicine (DCAM). The Core currently works with 169 cancer clinical studies representing 5 UCCCC Programs, and a few tissue procurement studies. Services provided by the PCF include: ? development and implementation of analytical assays for measurement of drugs and metabolites in biological fluids ? pharmacokinetic design and writing assistance for clinical protocols; ? pharmacokinetic/pharmacodynamic modeling; ? research phlebotomy and intravenous cannulation; ? sample processing; ? urine collection; ? specimen storage, tracking and archiving;and ? electrocardiograms.

Public Health Relevance

The research supported by the PCF aims at improving the quality of life and outcome of cancer patients. We help clinical investigators individualize chemotherapy to optimize treatment effectiveness and minimize toxicity. We also facilitate discovery and measurement of biomarkers correlating with pharmacological response to a drug or disease progression.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014599-38
Application #
8486644
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-04-01
Project End
2018-03-31
Budget Start
2013-04-23
Budget End
2014-03-31
Support Year
38
Fiscal Year
2013
Total Cost
$71,681
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Luke, Jason J; Lemons, Jeffrey M; Karrison, Theodore G et al. (2018) Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 36:1611-1618
Wang, Amy Y; Weiner, Howard; Green, Margaret et al. (2018) A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol 11:4
Sample, Ashley; He, Yu-Ying (2018) Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 34:13-24
Jeong, Choongwon; Witonsky, David B; Basnyat, Buddha et al. (2018) Detecting past and ongoing natural selection among ethnically Tibetan women at high altitude in Nepal. PLoS Genet 14:e1007650
Wang, Xin; Wu, Xingye; Zhang, Zhonglin et al. (2018) Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 8:17914
Brown, Hailey M; Biering, Scott B; Zhu, Allen et al. (2018) Demarcation of Viral Shelters Results in Destruction by Membranolytic GTPases: Antiviral Function of Autophagy Proteins and Interferon-Inducible GTPases. Bioessays 40:e1700231
Karrison, Theodore; Kocherginsky, Masha (2018) Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials 15:178-188
An, Ningfei; Khan, Saira; Imgruet, Molly K et al. (2018) Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood 131:2682-2697
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74

Showing the most recent 10 out of 668 publications